Literature DB >> 1757540

Development of a rapid enzyme immunoassay for Clostridium difficile toxin A and its use in the diagnosis of C. difficile-associated disease.

J R DiPersio1, F J Varga, D L Conwell, J A Kraft, K J Kozak, D H Willis.   

Abstract

A rapid (2.5 h) direct enzyme immunoassay (EIA) for Clostridium difficile toxin A was developed for clinical use. Specimen centrifugation and filtration were not required. The EIA detected toxin A levels in patient stool as low as 20 pg (2 ng/ml of stool). The test was 5,000 times more sensitive for toxin A than it was for toxin B and did not react with a panel of other bacterial species with the exception of one highly toxigenic strain of Clostridium sordellii. The EIA was compared with the cytotoxin assay, culture of toxigenic C. difficile (toxigenic culture), and latex agglutination by using 313 fresh stool specimens submitted from patients with suspected C. difficile-associated disease. Results read visually and with a plate reader were similar. Sixty-two specimens were positive by one or more tests, but only 22 (35%) were positive by all four laboratory methods. The EIA was 84.1% sensitive and 98.9% specific when it was compared with the cytotoxin assay. The use of toxigenic culture to referee discrepant results (EIA versus cytotoxin assay) showed the EIA sensitivity and specificity to be 95.1 and 99.3%, respectively, with respect to other laboratory methods. Patient charts were reviewed for antibiotic-associated diarrhea on 108 specimens, including all those that were positive by at least one test method. Of 34 patients determined to have C. difficile-associated disease, 29 (85.3%) were positive by EIA, 32 (94.1%) were positive by the cytotoxin assay, 27 (79.4%) were positive by toxigenic culture, and 20 (58.8%) were positive by latex agglutination. Seven patients with antibiotic-associated diarrhea had a positive latex result, but results were negative by EIA, the cytotoxin assay, and toxigenic culture. The EIA demonstrated high specificity and good sensitivity for C. difficile-associated disease cases. The test can be used alone or in combination with the cytotoxin assay or toxigenic culture to provide rapid and sensitive results.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1757540      PMCID: PMC270422          DOI: 10.1128/jcm.29.12.2724-2730.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

1.  Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal Gal alpha 1-3Gal beta 1-4GlcNAc sequences.

Authors:  G F Clark; H C Krivan; T D Wilkins; D F Smith
Journal:  Arch Biochem Biophys       Date:  1987-08-15       Impact factor: 4.013

2.  Nosocomial acquisition of Clostridium difficile infection.

Authors:  L V McFarland; M E Mulligan; R Y Kwok; W E Stamm
Journal:  N Engl J Med       Date:  1989-01-26       Impact factor: 91.245

3.  Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease.

Authors:  R C Walker; P J Ruane; J E Rosenblatt; D M Lyerly; C A Gleaves; T F Smith; P F Pierce; T D Wilkins
Journal:  Diagn Microbiol Infect Dis       Date:  1986-05       Impact factor: 2.803

4.  Evaluation of a commercial kit for the routine detection of Clostridium difficile cytotoxin by tissue culture.

Authors:  T C Wu; S M Gersch
Journal:  J Clin Microbiol       Date:  1986-04       Impact factor: 5.948

5.  Results of a prospective, 18-month clinical evaluation of culture, cytotoxin testing, and culturette brand (CDT) latex testing in the diagnosis of Clostridium difficile-associated diarrhea.

Authors:  L R Peterson; M M Olson; C J Shanholtzer; D N Gerding
Journal:  Diagn Microbiol Infect Dis       Date:  1988-06       Impact factor: 2.803

6.  Commercial latex agglutination test for detection of Clostridium difficile-associated diarrhea.

Authors:  M T Kelly; S G Champagne; C H Sherlock; M A Noble; H J Freeman; J A Smith
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

7.  Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc.

Authors:  H C Krivan; G F Clark; D F Smith; T D Wilkins
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

8.  Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.

Authors:  G Corthier; M C Muller; T D Wilkins; D Lyerly; R L'Haridon
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

9.  Detection of Clostridium difficile toxins A (enterotoxin) and B (cytotoxin) in clinical specimens. Evaluation of a latex agglutination test.

Authors:  L R Peterson; J J Holter; C J Shanholtzer; C R Garrett; D N Gerding
Journal:  Am J Clin Pathol       Date:  1986-08       Impact factor: 2.493

10.  Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations.

Authors:  R Viscidi; S Willey; J G Bartlett
Journal:  Gastroenterology       Date:  1981-07       Impact factor: 22.682

View more
  20 in total

1.  Monoclonal antibodies specific for Clostridium difficile toxin B and their use in immunoassays.

Authors:  F Müller; C Stiegler; U Hadding
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

2.  Evaluation of an enzyme immunoassay for detection of Clostridium difficile toxin A.

Authors:  K Tsimidis; A E Simor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-06       Impact factor: 3.267

3.  Evaluation of a new enzyme immunoassay for Clostridium difficile toxin A.

Authors:  S O Vargas; D Horensky; A B Onderdonk
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

4.  Comparison of culture, cytotoxin assay and two EIA tests with clinical diagnosis of Clostridium difficile-associated diarrhea.

Authors:  M Binning; M A John; B C Schieven; T W Austin; R Lannigan; Z Hussain
Journal:  Can J Infect Dis       Date:  1994-07

5.  Diarrhea recurrence in patients with Clostridium difficile-associated diarrhea: Role of concurrent antibiotics.

Authors:  M Alfa; G Harding; A Ronald; R Light; N Macfarlane; N Olson; P Degagne; K Kasdorf; A Simor; K Macdonald; L Louie
Journal:  Can J Infect Dis       Date:  1999-07

6.  Detection of Clostridium difficile toxin by enzyme immunoassay, tissue culture test and culture.

Authors:  O Liesenfeld; F Saeger; H Hahn
Journal:  Infection       Date:  1994 Jan-Feb       Impact factor: 3.553

7.  Evaluation of three commercial enzyme immunoassay kits for detecting faecal Clostridium difficile toxins.

Authors:  S A Arrow; L Croese; R A Bowman; T V Riley
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

Review 8.  Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy.

Authors:  Munshi Moyenuddin; John C Williamson; Christopher A Ohl
Journal:  Curr Gastroenterol Rep       Date:  2002-08

9.  Shedding of Clostridium difficile, fecal beta-lactamase activity, and gastrointestinal symptoms in 51 volunteers treated with oral cefixime.

Authors:  E Chachaty; C Bourneix; S Renard; M Bonnay; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

10.  Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea.

Authors:  F Barbut; C Kajzer; N Planas; J C Petit
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.